Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization

Emerging in November 2021, the SARS-CoV-2 Omicron variant of concern exhibited marked immune evasion resulting in reduced vaccine effectiveness against SARS-CoV-2 infection and symptomatic disease. Most vaccine effectiveness data on Omicron are derived from the first Omicron subvariant, BA.1, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Feikin, Daniel R., Higdon, Melissa M., Andrews, Nick, Collie, Shirley, Deloria Knoll, Maria, Kwong, Jeffrey C., Link-Gelles, Ruth, Pilishvili, Tamara, Patel, Minal K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
WHO Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910025/
https://www.ncbi.nlm.nih.gov/pubmed/36797097
http://dx.doi.org/10.1016/j.vaccine.2023.02.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910025/
https://www.ncbi.nlm.nih.gov/pubmed/36797097
http://dx.doi.org/10.1016/j.vaccine.2023.02.020

Ejemplares similares